Savara shares fall as FDA says it will miss molgramostim BLA action date
Savara shares drop after the FDA said it will not meet the scheduled action date for the molgramostim biologics license application.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Seeking Alpha, Savara shares are falling after the FDA said it will not meet the agreed action date for the molgramostim biologics license application. The delay means the regulator's decision on the drug is pushed back.
why it matters
For investors in small biotech companies, FDA review deadlines matter, and a missed date usually adds uncertainty to plans for bringing a drug to market.
tags
instruments
sources
- Savara drops after FDA says it will not meet molgramostim BLA action date — Seeking Alpha, 20 November 2026 at 16:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗